Letters to the Editor
Vol. 16 No. 1 (2024): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY
Long-lasting disease remission with third line therapy with gilteritinib
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: September 26, 2024
Accepted: October 1, 2024
Accepted: October 1, 2024
956
Views
442
Downloads
126
HTML
Authors
Limited data are available on the effectiveness of gilteritinib as a third-line salvage therapy in patients with acute myeloid leukemia (AML). We present an elderly patient who achieved sustained remission following gilteritinib monotherapy as a third-line treatment after failing two prior regimens.
Downloads
Download data is not yet available.
Citations
How to Cite
“SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY: Long-lasting disease remission with third line therapy with gilteritinib” (2024) Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024079. doi:10.4084/MJHID.2024.079.
Copyright (c) 2024 matteo molica
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
